Gene

FGFR3

fibroblast growth factor receptor 3

Explore in graph →CI-GENE-00001926HGNC:3690 ENSG00000068078 NCBI 2261 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (214)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 101–150 of 214 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FGFR3 L608V1
Infigratinib	Transitional Cell Carcinoma	Predictive	C	Supports Resistance	1	submitted	EID6407 In this one-arm study, 67 patients with metastastic urothelial carcinoma and diverse FGFR3 alterations were treated with pan-FGFR Inhibitor BGJ398. The majority of patients (70.1%) had received two or…

Cohorts

Alteration frequency by cohort (100)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved100 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Bladder Cancer (MSK, Clin Cancer Res 2023) bladder_msk_2023	unmapped	Ssm	443	526

Literature

Linked publications (36)

25 per page, newest first.

pubmedPublishedShowing 1–25 of 36 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
· N Engl J Med · 2019 · PMID 31340094 · validated civic_curation pubmed
FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population.
· Cancer Epidemiol · 2010 · PMID 20542753 · validated civic_curation pubmed
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.
· J Clin Oncol · 2017 · PMID 27870574 · validated civic_curation pubmed
Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy.
· EBioMedicine · 2018 · PMID 29941343

FGFR3 L645H1
(oncogenic)	Malignant NeoplasmALIAS	Oncogenic	D	Supports Oncogenicity	1	submitted	EID12884 In a saturation mutagenesis study, all possible point mutations in the FGFR 1-4 kinase domain (amino acids 472-807 for FGFR3) were tested. Lentiviral plasmids were infected at MOI < 0.3 into the growt… (full text at CIViC) PMID 41361008 · Tangermann et al., 2025 · Open in CIViC	civic

FGFR3 L645H1

(oncogenic)

Malignant NeoplasmALIAS

Oncogenic

Supports Oncogenicity

submitted

EID12884

In a saturation mutagenesis study, all possible point mutations in the FGFR 1-4 kinase domain (amino acids 472-807 for FGFR3) were tested. Lentiviral plasmids were infected at MOI < 0.3 into the growt… (full text at CIViC)

PMID 41361008 · Tangermann et al., 2025 · Open in CIViC

FGFR3 M528I3
(predisposing)	HypochondroplasiaUNRESOLVED	Predisposing	C	Supports Predisposition	3	submitted	EID9706 Novel variant found through WES on all affected individuals of a family with short stature. The segregation of the variant was confirmed by sanger sequencing (ACMG: PP1). The affected members presente… (full text at CIViC) PMID 25777271 · Kant et al., 2015 · Open in CIViC	civic
(functional)	—UNRESOLVED	Functional	C	Supports Gain Of Function	3	submitted	EID9948 Novel variant found through WES on all affected individuals of a family with short stature (ACMG: PP1). The variant was predicted to be possibly damaging in several in-silico predictors (align GVGD, S… (full text at CIViC) PMID 25777271 · Kant et al., 2015 · Open in CIViC	civic
(oncogenic)	Malignant NeoplasmALIAS	Oncogenic	D	Supports Oncogenicity	2	submitted	EID12878 In a saturation mutagenesis study, all possible point mutations in the FGFR 1-4 kinase domain (amino acids 472-807 for FGFR3) were tested. Lentiviral plasmids were infected at MOI < 0.3 into the growt… (full text at CIViC) PMID 41361008 · Tangermann et al., 2025 · Open in CIViC	civic

FGFR3 Mutation6
(prognostic)	Malignant Bladder NeoplasmALIAS	Prognostic	B	Does Not Support Better Outcome	3	submitted	EID9258 The authors screened 85 superficial bladder tumor patients (35 with early-stage (stage Ta/grade 1-2) and 50 with an advanced stage (stage T1 or grade 3)) for variants in FGFR3 and TP53 genes. FGFR3 ac… (full text at CIViC) PMID 16278391 · Zieger et al., 2005 · Open in CIViC	civic
Cisplatin + GemcitabineCombination	Malignant Bladder NeoplasmALIAS	Predictive	B	Supports Sensitivity Response	3	accepted	EID7566 In this study, 52 patients with Muscle Invasive Bladder Cancer (MIBC) were randomly selected and administered neoadjuvant cisplatin and gemcitabine chemotherapy. 39 out of 52 patients showed pathologi… (full text at CIViC) PMID 29941343 · Yang et al., 2018 · Open in CIViC	civic
Erdafitinib	Transitional Cell Carcinoma	Predictive	A	Supports Sensitivity Response	4	rejected	EID7263 Patients with metastatic or unresectable urothelial carcinoma havoring FGFR2 fusion, FGFR3 fusion or FGFR3 mutation were treated with pan-FGFR inhibitor, erdafitinib, in Phase 2 trial. 96 patients wer… (full text at CIViC) Open in CIViC	civic
〃	Transitional Cell Carcinoma	Predictive	A	Supports Sensitivity Response	4	accepted	EID7422 In a phase 2 trial, patients with locally advanced and unresectable or metastatic urothelial carcinoma harboring FGFR3 mutation or FGFR2/3 fusion were treated with Erdafitinib. All the patients had a … (full text at CIViC) PMID 31340094 · Loriot et al., 2019 · Open in CIViC	civic
〃	Bladder Urothelial Carcinoma	Predictive	B	Supports Sensitivity Response	3	submitted	EID10397 Phase I dose-escalation cohort (NCT01703481) of patients with advanced solid tumors in which antineoplastic therapy was no longer effective using pan-FGFR inhibitor JNJ-42756493. All 16 patients with … (full text at CIViC) PMID 31088831 · Bahleda et al., 2019 · Open in CIViC	civic
Infigratinib	Bladder Carcinoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID1910 Phase 1 study evaluated 132 patients who had advanced cancer with FGFR-aberrations treated with FGFR-inhibitor BGJ398. In the subgroup of eight patients with FGFR3-mutated bladder/urothelial cancer tr… (full text at CIViC) PMID 27870574 · Nogova et al., 2017 · Open in CIViC	civic

FGFR3 Overexpression5
Dovitinib	Multiple Myeloma	Predictive	D	Does Not Support Sensitivity Response	2	submitted	EID12294 Multiple myeloma (MM) is a neoplastic disorder of clonal B cells characterised by uncontrolled and aberrant proliferation of plasma cells within bone marrow, monoclonal protein in the blood or urine, … (full text at CIViC) PMID 25402977 · Scheid et al., 2015 · Open in CIViC	civic
Dovitinib + PD173074 + Tyrosine Kinase Inhibitor SU5402Substitutes	Bladder Carcinoma	Predictive	D	Supports Sensitivity Response	3	accepted	EID803 The effects of FGFR inhibitors (PD173074, TKI-258 and SU5402) in bladder carcinoma cell lines were related to FGFR3 (and/or FGFR1) expression. PMID 21119661 · Lamont et al., 2011 · Open in CIViC	civic
R3Mab	Multiple Myeloma	Predictive	D	Supports Sensitivity Response	4	rejected	EID10363 Pro-B Ba/F3 cells transfected with wild type FGFR3 resulted in Il-3 independence with FGF1 dependence for growth. Monoclonal antibody R3Mab treatment in addition to FGF1 resulted in suppression of pro… (full text at CIViC) PMID 19381019 · Qing et al., 2009 · Open in CIViC	civic
〃	Multiple Myeloma	Predictive	D	Supports Sensitivity Response	4	submitted	EID10364 Pro-B Ba/F3 cells transfected with wild type FGFR3 resulted in Il-3 independence with FGF1 dependence for growth. Monoclonal antibody R3Mab treatment in addition to FGF1 resulted in suppression of pro… (full text at CIViC) PMID 19381019 · Qing et al., 2009 · Open in CIViC	civic
〃	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID10352 Pro-B Ba/F3 cells transfected with wild type FGFR3 resulted in Il-3 independence with FGF1 dependence for growth. Monoclonal antibody R3Mab treatment in addition to FGF1 resulted in suppression of pr… (full text at CIViC) PMID 19381019 · Qing et al., 2009 · Open in CIViC	civic